A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma

Full Title

A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)

Purpose

Researchers want to find the best dose of BMS-986458 to use alone and with rituximab to treat lymphoma. The people in this study have non-Hodgkin lymphoma (NHL) that came back or keeps growing after treatment.

BMS-986458 breaks down a protein called BCL6 by binding to another protein called cereblon. BCL6 helps lymphoma cells survive and grow. By breaking down BCL6, BMS-986458 may slow lymphoma growth.

If you join this study, you will get BMS-986458 alone or with rituximab. BMS-986458 is taken orally (by mouth) and rituximab is given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Jennifer Lue’s office at 646-608-4160.